DK2049506T5 - Modulatorer af terapeutikas farmakokinetiske egenskaber - Google Patents

Modulatorer af terapeutikas farmakokinetiske egenskaber Download PDF

Info

Publication number
DK2049506T5
DK2049506T5 DK07836007.0T DK07836007T DK2049506T5 DK 2049506 T5 DK2049506 T5 DK 2049506T5 DK 07836007 T DK07836007 T DK 07836007T DK 2049506 T5 DK2049506 T5 DK 2049506T5
Authority
DK
Denmark
Prior art keywords
compound
mmol
mixture
added
thf
Prior art date
Application number
DK07836007.0T
Other languages
English (en)
Other versions
DK2049506T3 (da
Inventor
Manoj C Desai
Allen Yu Hong
Hongtao Liu
Lianhong Xu
Randall W Vivian
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2049506(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of DK2049506T3 publication Critical patent/DK2049506T3/da
Application granted granted Critical
Publication of DK2049506T5 publication Critical patent/DK2049506T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Claims (12)

  1. MODULATORER AF TERAPEUTIKAS FARMAKOKINETISKE EGENSKABER PATENTKRAV
    1. Forbindelse med formlen IIB:
    eller et/en farmaceutisk acceptabell/acceptabel salt, solvat, stereoisomer og/eller ester deraf, hvor: R10a og R10b hver uafhængigt er FI eller -C'i^-alkyl; R12 er H eller -CH3; R13 er H, -C^-alkyl, -(CH2)0.iCR17R18OR19, -(CH2)0.3CR17R18NR20R21, -(CH2)0. 3CR17R18NR17C(O)NR20R21, -(CH2)1.3C(0)R22, -(CH2)i_3S(0)2R22 eller -(CH2)1.3-R23; R14 og R15 hver uafhængigt er H, -C^-alkyl eller arylalkyl; R17 og R18 hver uafhængigt er FI eller -Cj^-alkyl; R19 er H, -CV4-alkyl eller-arylalkyl; R20 og R21 hver uafhængigt er FI, -Ci.3-alkyl, -C(0)R17 eller -S(0)2R17; eller R20 og R21, sammen med det nitrogenatom, hvortil de er bundet, danner en ikke-substitueret eller substitueret 5-6-leddet heterocyclylring indeholdende 1-2 heteroatomer udvalgt fra gmppen bestående af N og O; R22 er H, -C^-alkyl, -OR19 eller -NR20R21; og R23 er en ikke-substitueret eller substitueret 5-6-leddet heterocyclylring indeholdende 1-2 heteroatomer udvalgt fra gruppen bestående af N og O; hvor den ikke-substituerede eller substituerede 5-6-leddede heterocyclylring dannet af R20 og R21 og den ikke-substituerede eller substituerede 5-6-leddede heterocyclylring af R23 hver uafhængigt er ikke-substitueret eller substitueret med en Ci_2-alkyl.
  2. 2. Forbindelse ifølge krav 1, hvor: R13 er -(CH2y3CR17R18NR20R21, -(CH2)0_3CR17R18NR17C(O)NR20R21 eller -(CH2)k;-R23.
  3. 3. Forbindelse ifølge krav 2, hvor: R13 er -(CH2)o_3CR17R18NR20R21 eller -(CH2y3CR17R18NR17C(O)-NR20R21.
  4. 4. Forbindelse ifølge krav 1 med formlen IIC:
    Formel IIC eller et/en farmaceutisk acceptabelt/acceptabel salt, solvat, stereoisomer og/eller ester deraf, hvor: R13 er H, -C14-alkyl, -(CH2)0.|CR17RISOR19, -(CH2V3CR17R18NR20R21, -(CH2)0. 3CR17R18NR17C(O)NR20R21, -(CH2)1.3C(0)R22 eller -(CH2)I4-R2i; R17 og R18 hver uafhængigt er H eller Ci_3-alkyl; R19 er H, -C14-alkyl eller -arylalkyl; R20 og R21 hver uafhængigt er H, -Ci.3-alkyl, -C(0)R17 eller -S(0)2R17; eller R20 og R21, sammen med det nitrogenatom, hvortil de er bundet, danner en 5-6-leddet heterocyclylring indeholdende 1-2 heteroatomer udvalgt fra gruppen bestående af N og O; R22 er H, -C^alkyl, -OR19 eller -NR20R21; og R23 er en ikke-substitueret eller substitueret 5-6-leddet heterocyclylring indeholdende 1-2 heteroatomer udvalgt fra gruppen bestående af N og O.
  5. 5. Forbindelse ifølge krav 1 med formlen
    eller et/en farmaceutisk acceptabelt/acceptabel salt, stereoisomer og/eller solvat deraf.
  6. 6. Forbindelse ifølge krav 5, der er:
    eller et farmaceutisk acceptabelt salt deraf.
  7. 7. Forbindelse ifølge krav 1, der udvalgt fra gruppen bestående af:
    eller farmaceutisk acceptable salte, solvater, estere og/eller stereoisomerer deraf.
  8. 8. Forbindelse ifølge krav 1, hvilken forbindelse er udvalgt fra gruppen bestående af
    Og
    eller farmaceutisk acceptable salte, solvater, estere og/eller stereoisomerer deraf.
  9. 9. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 8, eller et/en farmaceutisk acceptabelt/acceptabel salt, solvat og/eller ester deraf og et farmaceutisk acceptabelt bærestof eller excipiens.
  10. 10. Forbindelse ifølge et hvilket som helst af kravene 1 til 8 til anvendelse i terapi.
  11. 11. Forbindelse ifølge et hvilket som helst af kravene 1 til 8 til anvendelse ved forbedring af farmakokinetik for et lægemiddel, der metaboliseres ved cytochrom P450 monooxygenase, øgning af blodplasmaniveauet for et lægemiddel, der metaboliseres ved cytochrom P450 monooxygenase, hæmning af cytochrom P450 monooxygenase, behandling af en HIV-infektion eller behandling af en HCV-infektion hos en patient.
  12. 12. Forbindelse til anvendelse ifølge krav 11, hvor den cytochrome P450 monooxygenase er cytochrom P450 monooxygenase 3A.
DK07836007.0T 2006-07-07 2007-07-06 Modulatorer af terapeutikas farmakokinetiske egenskaber DK2049506T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81931506P 2006-07-07 2006-07-07
US83237106P 2006-07-21 2006-07-21
US90322807P 2007-02-23 2007-02-23
PCT/US2007/015604 WO2008010921A2 (en) 2006-07-07 2007-07-06 Modulators of pharmacokinetic properties of therapeutics

Publications (2)

Publication Number Publication Date
DK2049506T3 DK2049506T3 (da) 2015-09-14
DK2049506T5 true DK2049506T5 (da) 2016-02-15

Family

ID=38729072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07836007.0T DK2049506T5 (da) 2006-07-07 2007-07-06 Modulatorer af terapeutikas farmakokinetiske egenskaber

Country Status (33)

Country Link
US (11) US7939553B2 (da)
EP (4) EP3112355B1 (da)
JP (2) JP4881433B2 (da)
KR (3) KR20140004808A (da)
CN (2) CN101490023B (da)
AP (1) AP2985A (da)
AR (1) AR061838A1 (da)
AU (1) AU2007275860C1 (da)
BR (1) BRPI0714055B8 (da)
CA (1) CA2653374A1 (da)
CY (2) CY1116688T1 (da)
DK (1) DK2049506T5 (da)
EA (2) EA020489B1 (da)
ES (3) ES2546378T3 (da)
FR (1) FR15C0078I2 (da)
HK (2) HK1232217A1 (da)
HR (2) HRP20090077B1 (da)
HU (1) HUE025565T4 (da)
IL (2) IL195488A (da)
LT (1) LTC2049506I2 (da)
LU (1) LU92864I2 (da)
ME (1) ME02258B (da)
MX (1) MX2009000234A (da)
NL (1) NL300780I2 (da)
NO (4) NO343776B1 (da)
NZ (1) NZ573060A (da)
PL (1) PL2049506T3 (da)
PT (2) PT2049506E (da)
RS (1) RS54237B9 (da)
SG (1) SG183007A1 (da)
SI (1) SI2049506T1 (da)
TW (2) TWI411613B (da)
WO (1) WO2008010921A2 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
AU2007275860C1 (en) * 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2465855A1 (en) * 2006-08-31 2012-06-20 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
LT3150586T (lt) * 2007-02-23 2020-03-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2013204815B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ME02628B (me) 2007-02-23 2017-06-20 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava lekova
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
PT2231628E (pt) * 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
US8993542B2 (en) 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
EA030123B1 (ru) 2009-02-06 2018-06-29 Джилид Сайэнс, Инк. Таблетка для лечения вич и способ лечения вич с ее применением
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
EP2418196A1 (en) * 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US20130280212A1 (en) * 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
US20140187771A1 (en) * 2011-05-02 2014-07-03 Gilead Sciences, Inc. Amorphous solid salts
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
JP5651275B2 (ja) 2011-08-16 2015-01-07 ギリアード サイエンシス インコーポレーテッド テノホビルアラフェナミドヘミフマレート
MX354958B (es) 2011-09-16 2018-03-27 Gilead Pharmasset Llc Metodos para el tratamiento de vhc.
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
AU2013207825A1 (en) 2012-01-12 2014-08-28 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
SG10201509336RA (en) * 2012-02-03 2015-12-30 Gilead Sciences Inc Methods and intermediates for preparing pharmaceutical agents
EP2819644A1 (en) 2012-03-01 2015-01-07 Gilead Sciences, Inc. Spray dried formulations
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
US20160200716A1 (en) * 2012-12-26 2016-07-14 Assia Chemical Industries Ltd. Cobicistat dichlohydrate salt
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US20170035911A1 (en) 2013-11-29 2017-02-09 Mylan Laboratories Ltd. Amorphous Cobicistat Solid Dispersion
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
WO2017160922A1 (en) 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
CN105884760B (zh) * 2016-06-13 2019-01-04 厦门市蔚嘉化学科技有限公司 一种可比司他中间体的制备方法
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
WO2018026835A1 (en) 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3518935A1 (en) 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3558304A2 (en) 2016-12-23 2019-10-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP7363810B2 (ja) * 2018-11-26 2023-10-18 三菱瓦斯化学株式会社 水系エポキシ樹脂組成物及びその硬化物
CN111329858B (zh) * 2018-12-18 2022-09-20 深圳先进技术研究院 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354866A (en) * 1966-04-25 1967-11-28 Frank D Karkoska Coating apparatus including means to rotate and translate a rod-substrate
US3882114A (en) * 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
US3957774A (en) * 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
DE3478684D1 (en) * 1983-11-02 1989-07-20 Magyar Tudomanyos Akademia Crown ether derivatives
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5556418A (en) * 1993-07-06 1996-09-17 Pappas; Panagiotis T. Method and apparatus for pulsed magnetic induction
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2174992T3 (es) 1992-12-29 2002-11-16 Abbott Lab Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999033792A2 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
AP1459A (en) 1999-10-06 2005-08-22 Tibotec Pharm Ltd Hexahydrofuro [2,3-b] furan-3- YL-N-{3-[(1,3- benzodioxol-5- ylsufonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.
US6252336B1 (en) 1999-11-08 2001-06-26 Cts Corporation Combined piezoelectric silent alarm/battery charger
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7285566B2 (en) 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
CA2472372C (en) 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
ATE443048T1 (de) 2002-11-20 2009-10-15 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
JP2004184681A (ja) * 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7737608B2 (en) 2003-07-30 2010-06-15 The Boeing Company Enhanced amplitude piezoelectric motor apparatus and method
JP2005091988A (ja) * 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
PL1677827T3 (pl) * 2003-10-27 2009-06-30 Vertex Pharma Połączenia do leczenia HCV
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP2006003701A (ja) * 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
JP5142714B2 (ja) * 2004-07-06 2013-02-13 アボット・ラボラトリーズ Ｈｉｖプロテアーゼ阻害薬のプロドラッグ
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
EP2465855A1 (en) 2006-08-31 2012-06-20 Abbott Laboratories Cytochrome P450 oxidase inhibitors and uses thereof
LT3150586T (lt) * 2007-02-23 2020-03-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
SG182229A1 (en) 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
JP5547067B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
DK2245456T3 (da) 2007-12-27 2013-03-04 Baxter Int Fremgangsmåde og sammensætninger til specifik påvisning af fysiologisk acceptable polymermolekyler
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EA030123B1 (ru) 2009-02-06 2018-06-29 Джилид Сайэнс, Инк. Таблетка для лечения вич и способ лечения вич с ее применением

Also Published As

Publication number Publication date
PT2487165T (pt) 2016-11-18
IL195488A (en) 2017-04-30
LTPA2015040I1 (lt) 2015-12-28
HRP20090077B1 (hr) 2016-04-08
CN103275033A (zh) 2013-09-04
WO2008010921A3 (en) 2008-07-10
HK1126485A1 (en) 2009-09-04
TWI496778B (zh) 2015-08-21
US8383655B2 (en) 2013-02-26
US20170143680A1 (en) 2017-05-25
ES2546378T3 (es) 2015-09-23
NO20090593L (no) 2009-04-07
US20150011775A1 (en) 2015-01-08
JP4881433B2 (ja) 2012-02-22
EP3112355B1 (en) 2020-04-29
EA201270738A1 (ru) 2013-07-30
EA200900155A1 (ru) 2009-06-30
BRPI0714055A2 (pt) 2012-12-18
PT2049506E (pt) 2015-10-09
CY2015046I1 (el) 2016-06-22
KR101636221B1 (ko) 2016-07-04
HUE025565T4 (en) 2017-01-30
US20080108617A1 (en) 2008-05-08
HK1232217A1 (zh) 2018-01-05
EP3696171A1 (en) 2020-08-19
IL195488A0 (en) 2009-09-01
RS54237B9 (sr) 2019-07-31
ES2611308T3 (es) 2017-05-08
CN101490023B (zh) 2013-05-29
KR20150042869A (ko) 2015-04-21
TW201412733A (zh) 2014-04-01
US20150225448A1 (en) 2015-08-13
CA2653374A1 (en) 2008-01-24
RS54237B1 (en) 2015-12-31
DK2049506T3 (da) 2015-09-14
SG183007A1 (en) 2012-08-30
US20160303088A1 (en) 2016-10-20
EP2049506B1 (en) 2015-06-17
JP2009542696A (ja) 2009-12-03
TWI411613B (zh) 2013-10-11
FR15C0078I2 (fr) 2016-04-22
ES2546378T9 (es) 2016-01-26
SI2049506T1 (sl) 2015-08-31
AU2007275860B2 (en) 2013-11-14
FR15C0078I1 (da) 2016-01-08
PL2049506T3 (pl) 2015-11-30
US20090291952A1 (en) 2009-11-26
HRP20150744T2 (hr) 2016-02-26
US20180221348A1 (en) 2018-08-09
AP2985A (en) 2014-09-30
US8067449B2 (en) 2011-11-29
LU92864I2 (fr) 2016-01-06
NO345343B1 (no) 2020-12-21
US7939553B2 (en) 2011-05-10
ME02258B (me) 2015-12-31
IL232320A0 (en) 2014-06-30
AU2007275860A1 (en) 2008-01-24
KR101477822B1 (ko) 2015-01-02
NO20190528A1 (no) 2009-04-07
KR20090028821A (ko) 2009-03-19
NO2019031I1 (no) 2019-07-19
CY2015046I2 (el) 2016-06-22
NO343776B1 (no) 2019-06-03
WO2008010921A2 (en) 2008-01-24
US20140105859A1 (en) 2014-04-17
US20160067360A1 (en) 2016-03-10
AP2008004720A0 (en) 2008-12-31
JP2012051933A (ja) 2012-03-15
BRPI0714055B8 (pt) 2021-05-25
CY1116688T1 (el) 2016-06-22
HRP20150744T1 (en) 2015-10-09
TW200811167A (en) 2008-03-01
LTC2049506I2 (lt) 2019-05-10
HRP20090077A2 (en) 2009-06-30
AR061838A1 (es) 2008-09-24
CN103275033B (zh) 2015-04-29
HUE025565T2 (en) 2016-03-29
NO2019027I1 (no) 2019-07-04
EP2049506A2 (en) 2009-04-22
NL300780I1 (da) 2016-03-15
NZ573060A (en) 2012-02-24
NL300780I2 (da) 2016-03-15
CN101490023A (zh) 2009-07-22
AU2007275860C1 (en) 2014-06-12
EP2487165B1 (en) 2016-09-14
BRPI0714055B1 (pt) 2019-05-21
ES2796275T3 (es) 2020-11-26
MX2009000234A (es) 2009-01-23
EP2487165A1 (en) 2012-08-15
EP2049506B9 (en) 2016-01-13
US9139541B2 (en) 2015-09-22
EP3112355A1 (en) 2017-01-04
EA020489B1 (ru) 2014-11-28
KR20140004808A (ko) 2014-01-13
US20130123311A1 (en) 2013-05-16
US20110212964A1 (en) 2011-09-01
EA025845B1 (ru) 2017-02-28

Similar Documents

Publication Publication Date Title
DK2049506T5 (da) Modulatorer af terapeutikas farmakokinetiske egenskaber
DK2487166T3 (da) Modulatorer af terapeutikas farmakokinetiske egenskaber
DK2487163T3 (da) Modulatorer af terapeutikas farmakokinetiske egenskaber
AU2015234299B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
AU2013204805C1 (en) Modulators of pharmacokinetic properties of therapeutics
NO20210811A1 (no) Modulatorer av farmakokinetikkegenskaper til terapeutika